Humacyte, Inc. WarrantHUMAW
About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
Employees: 220
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 5 [Q4 2024] → 5 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.37% [Q4 2024] → 0.35% (-0.01%) [Q1 2025]
81% less capital invested
Capital invested by funds: $806K [Q4 2024] → $157K (-$650K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for HUMAW.
Financial journalist opinion
We haven’t received any recent news articles for HUMAW.